Asset Management
Compare Stocks
2 / 10Stock Comparison
INV vs XOMA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
INV vs XOMA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Asset Management | Biotechnology |
| Market Cap | $349M | $490M |
| Revenue (TTM) | $1M | $52M |
| Net Income (TTM) | $-317M | $29M |
| Gross Margin | -271.2% | 94.3% |
| Operating Margin | -63.2% | 21.8% |
| Forward P/E | — | 36.7x |
| Total Debt | $28M | $132M |
| Cash & Equiv. | $11M | $83M |
INV vs XOMA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Innventure, Inc. (INV) | 100 | 62.1 | -37.9% |
| XOMA Royalty Corp. (XOMA) | 100 | 201.3 | +101.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INV vs XOMA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INV is the clearest fit if your priority is dividends.
- 0.2% yield, 1-year raise streak, vs XOMA's 0.7%
XOMA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.21, yield 0.7%
- Rev growth 83.1%, EPS growth 188.5%, 3Y rev CAGR 105.3%
- 186.7% 10Y total return vs INV's -37.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 83.1% revenue growth vs INV's 9.2% | |
| Quality / Margins | 56.4% margin vs INV's -64.1% | |
| Stability / Safety | Beta 1.21 vs INV's 2.63 | |
| Dividends | 0.2% yield, 1-year raise streak, vs XOMA's 0.7% | |
| Momentum (1Y) | +68.7% vs INV's +59.2% | |
| Efficiency (ROA) | 12.1% ROA vs INV's -47.4%, ROIC 7.4% vs -14.8% |
INV vs XOMA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
XOMA leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
XOMA is the larger business by revenue, generating $52M annually — 42.7x INV's $1M. XOMA is the more profitable business, keeping 56.4% of every revenue dollar as net income compared to INV's -64.1%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1M | $52M |
| EBITDAEarnings before interest/tax | -$451M | $14M |
| Net IncomeAfter-tax profit | -$317M | $29M |
| Free Cash FlowCash after capex | -$87M | $3M |
| Gross MarginGross profit ÷ Revenue | -2.7% | +94.3% |
| Operating MarginEBIT ÷ Revenue | -63.2% | +21.8% |
| Net MarginNet income ÷ Revenue | -64.1% | +56.4% |
| FCF MarginFCF ÷ Revenue | -40.2% | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +57.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.3% | +157.8% |
Valuation Metrics
INV leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $349M | $490M |
| Enterprise ValueMkt cap + debt − cash | $366M | $538M |
| Trailing P/EPrice ÷ TTM EPS | -3.55x | 28.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 36.74x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.12x |
| EV / EBITDAEnterprise value multiple | — | 37.50x |
| Price / SalesMarket cap ÷ Revenue | 286.17x | 9.39x |
| Price / BookPrice ÷ Book value/share | 0.36x | 8.85x |
| Price / FCFMarket cap ÷ FCF | — | 170.55x |
Profitability & Efficiency
XOMA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
XOMA delivers a 31.9% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-59 for INV. INV carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.57x. On the Piotroski fundamental quality scale (0–9), XOMA scores 5/9 vs INV's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -58.9% | +31.9% |
| ROA (TTM)Return on assets | -47.4% | +12.1% |
| ROICReturn on invested capital | -14.8% | +7.4% |
| ROCEReturn on capital employed | -18.1% | +5.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.04x | 1.57x |
| Net DebtTotal debt minus cash | $17M | $49M |
| Cash & Equiv.Liquid assets | $11M | $83M |
| Total DebtShort + long-term debt | $28M | $132M |
| Interest CoverageEBIT ÷ Interest expense | -57.53x | 2.90x |
Total Returns (Dividends Reinvested)
XOMA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XOMA five years ago would be worth $13,005 today (with dividends reinvested), compared to $6,210 for INV. Over the past 12 months, XOMA leads with a +68.7% total return vs INV's +59.2%. The 3-year compound annual growth rate (CAGR) favors XOMA at 31.3% vs INV's -15.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +38.6% | +47.5% |
| 1-Year ReturnPast 12 months | +59.2% | +68.7% |
| 3-Year ReturnCumulative with dividends | -40.0% | +126.1% |
| 5-Year ReturnCumulative with dividends | -37.9% | +30.0% |
| 10-Year ReturnCumulative with dividends | -37.9% | +186.7% |
| CAGR (3Y)Annualised 3-year return | -15.7% | +31.3% |
Risk & Volatility
XOMA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XOMA is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than INV's 2.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XOMA currently trades 96.4% from its 52-week high vs INV's 83.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.63x | 1.21x |
| 52-Week HighHighest price in past year | $7.45 | $42.81 |
| 52-Week LowLowest price in past year | $2.36 | $22.29 |
| % of 52W HighCurrent price vs 52-week peak | +83.4% | +96.4% |
| RSI (14)Momentum oscillator 0–100 | 66.0 | 71.1 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 242K |
Analyst Outlook
Evenly matched — INV and XOMA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Consensus price targets imply 30.2% upside for XOMA (target: $54) vs 28.8% for INV (target: $8). For income investors, XOMA offers the higher dividend yield at 0.74% vs INV's 0.24%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | $8.00 | $53.75 |
| # AnalystsCovering analysts | — | 10 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | +0.7% |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | $0.01 | $0.30 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.3% |
XOMA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). INV leads in 1 (Valuation Metrics). 1 tied.
INV vs XOMA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is INV or XOMA a better buy right now?
For growth investors, XOMA Royalty Corp.
(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus 9. 2% for Innventure, Inc. (INV). XOMA Royalty Corp. (XOMA) offers the better valuation at 28. 3x trailing P/E (36. 7x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INV or XOMA?
Over the past 5 years, XOMA Royalty Corp.
(XOMA) delivered a total return of +30. 0%, compared to -37. 9% for Innventure, Inc. (INV). Over 10 years, the gap is even starker: XOMA returned +186. 7% versus INV's -37. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INV or XOMA?
By beta (market sensitivity over 5 years), XOMA Royalty Corp.
(XOMA) is the lower-risk stock at 1. 21β versus Innventure, Inc. 's 2. 63β — meaning INV is approximately 117% more volatile than XOMA relative to the S&P 500. On balance sheet safety, Innventure, Inc. (INV) carries a lower debt/equity ratio of 4% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — INV or XOMA?
By revenue growth (latest reported year), XOMA Royalty Corp.
(XOMA) is pulling ahead at 83. 1% versus 9. 2% for Innventure, Inc. (INV). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -143. 1% for Innventure, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INV or XOMA?
XOMA Royalty Corp.
(XOMA) is the more profitable company, earning 60. 8% net margin versus -64. 1% for Innventure, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMA leads at 21. 8% versus -63. 2% for INV. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is INV or XOMA more undervalued right now?
Analyst consensus price targets imply the most upside for XOMA: 30.
2% to $53. 75.
07Which pays a better dividend — INV or XOMA?
All stocks in this comparison pay dividends.
XOMA Royalty Corp. (XOMA) offers the highest yield at 0. 7%, versus 0. 2% for Innventure, Inc. (INV).
08Is INV or XOMA better for a retirement portfolio?
For long-horizon retirement investors, XOMA Royalty Corp.
(XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), 0. 7% yield, +186. 7% 10Y return). Innventure, Inc. (INV) carries a higher beta of 2. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XOMA: +186. 7%, INV: -37. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between INV and XOMA?
These companies operate in different sectors (INV (Financial Services) and XOMA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INV is a small-cap quality compounder stock; XOMA is a small-cap high-growth stock. XOMA pays a dividend while INV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Compare XOMA vs RPRX
RPRX is one of the most direct listed alternatives to XOMA.
Compare INV vs GCBC
GCBC overlaps with INV in an adjacent operating segment worth comparing.
Expand With RPRX + BCYC
RPRX and BCYC are the strongest missing peers across the current compare set.